SCHWARTZ, METZ & WISE, P.A.

ATTORNEYS

Tel: 410-244-7000		20 West Street Annapolis, Maryland 21401	Fax: 410-269-5443	
TO:	Members, Hou	orable Peter A. Hammen, Chair , House Health and Government Operations Committee orable Thomas M. Middleton		
FROM:	J. Steven Wise	Pamela Metz Kasemeyer J. Steven Wise Danna L. Kauffman		
DATE:	March 22, 2010	March 22, 2016		
RE:		SUPPORT – Senate Bill 97 – Public Health – Opioid-Associated Disease Preventio and Outreach Programs		

On behalf of the Maryland State Medical Society (MedChi), the Mid-Atlantic Association of Community Health Centers (MACHC) and the Maryland Chapter of the American Academy of Pediatrics (MDAAP), we support Senate Bill 97.

Senate Bill 97 authorizes the establishment of sterile needle exchange programs statewide. Based on the successful programs that have been operational in Baltimore City and Prince George's County, this legislation seeks to expand and enhance the proven efficacy of these programs and establishes a framework that reflects the history, experience, expertise and positive outcomes demonstrated by the existing programs.

The evidence is undisputed – sterile needle exchange programs are a cost-effective approach to preventing the transmission of infectious diseases such as HIV, Hepatitis B, and Hepatitis C, which are often transmitted between persons that inject drugs. These programs are able to engage these individuals in infectious disease screening, referral for treatment, long-term care or pre-exposure prophylaxis. They have demonstrated a marked reduction in the incidence of HIV and Hepatitis C in areas in which the programs operate.

Syringe exchange programs also enhance the collection of data and information on substancerelated disorder trends and patterns. Overdose deaths in Maryland have increased dramatically. Syringe exchange programs provide an opportunity to administer overdose prevention education and distribute naloxone directly to individuals at risk of overdose. They also create an opportunity to link individuals who inject drugs to substance-related disorder treatment and other health services.

Expansion of these cost-effective programs statewide is a critical component of Maryland's commitment to addressing the increasing incidence of overdose deaths, infectious diseases, and related health and social consequences associated with injected drug use. They are programs that have been supported by law enforcement in addition to public health officials. It is essential they be authorized statewide. A favorable report on Senate Bill 97 is requested.

For more information call:

Pamela Metz Kasemeyer J. Steven Wise Danna L. Kauffman (410) 244-7000